US Hydrocephalus Shunts Market is expected to reach US$ 146.24 million by 2030

Ventriculo-Peritoneal Segment Held Larger Share of US Hydrocephalus Shunts Market

According to our new research study on “US Hydrocephalus Shunts Market Forecast to 2030 – Country Analysis – by Product, Type, Age Group, End User, and Country,” the US Hydrocephalus Shunts market size is expected to reach US$ 146.24 million by 2030 from US$ 109.61 million in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030.

Based on the type, the US hydrocephalus shunts is segmented into ventriculoperitoneal, ventriculo-atrial, ventriculo-pleural, and lumbo-peritoneal. The ventriculoperitoneal segment held a larger market share in 2022 and the same segment is anticipated to register a higher CAGR during 2022-2030. A ventriculoperitoneal (VP) shunt reduces the pressure exerted on the brain by fluid accumulation by diverting CSF from the brain's ventricles into the peritoneal cavity, the slot in the abdomen near the digestive organs. Ventriculoperitoneal (VP) shunts are among the most used tools for treating hydrocephalus. The tip of a distal catheter is placed in a cavity near the loops of the intestine and bowel. The CSF shunted is reabsorbed into the bloodstream and is eventually eliminated through normal urination. Ventriculo-peritoneal (VP) shunt procedure usually takes 90 minutes, followed by 3–4 days of recovery. Patients are discharged within 7 days after the procedure.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00030116

According to a research paper published in the National Center for Biotechnology Information (NCBI), a VP shunt greatly impacts advanced neurosurgical patient care. VP shunt can be lifesaving for benign disorders. However, for malignant tumors, the results are usually poor; often, these patients die from other causalities that aren’t related to the shunt. The possibility of VP shunt-related complications in emergency departments is high, ranging from 2% to 20%. Additionally, ~5–10% of neonates and young children require shunt revision.

B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc,      Natus Medical Inc, Anuncia Inc, Desu Medical are among the leading companies operating in the US hydrocephalus shunts market.

A surge in funding from public and private organizations to fuel the R&D of medical devices has benefited the hydrocephalus shunts market. Hydrocephalus Association is one of the private organizations in the US that funds the research for hydrocephalus. The association invests in research to improve therapeutic outcomes and prevent hydrocephalus incidences among people.

A few of the funds associated with hydrocephalus shunts are mentioned below:

• From 2009 to 2022, the Hydrocephalus Clinical Research Network (HCRN) helped secure funds for 3 randomized control trials to compare treatment options. It also obtained a US$ 10 million NIH grant to run a randomized control trial for comparing shunt to endoscopic third ventriculostomy (ETV)with choroid plexus cauterization (CPC) among children under 2.
• Under the national campaign “Roadmap to a Cure,” the Hydrocephalus Association invested US$ 20 million as of 2020 to strengthen research and treatment support for curing hydrocephalus. Since 2009, the Hydrocephalus Association has cumulatively spent over US$ 12 million in research programs, and in one of the trials, the researchers reported a 36% decrease in shunt infection rates. The following graph represents the cumulative research spending by the Hydrocephalus Association since 2009.
• In August 2021, researchers at the Department of Neurosurgery of the Johns Hopkins Cerebral Fluid Center received a grant of US$ 14 million from the National Institute of Neurological Disorders and Stroke (NINDS). This was conducted in collaboration with the Adult Hydrocephalus Clinical Research Network (AHCRN) and coordinated by the Hydrocephalus Association. Hydrocephalus Association raises awareness and supports hydrocephalus research. The research is expected to prove whether shunt surgery significantly helps patients with idiopathic normal pressure hydrocephalus (iNPH).
• In June 2022, CereVasc, Inc. raised US$ 43.9 million in series A financing to support the human trial of the eShunt system.

Thus, an upsurge in funding for R&D and clinical trials associated with hydrocephalus shunts provides growth opportunities for the US hydrocephalus shunt market.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com